continuing review SOP – Clinical Research Made Simple https://www.clinicalstudies.in Trusted Resource for Clinical Trials, Protocols & Progress Sat, 23 Aug 2025 08:01:33 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.1 How to Develop SOPs for Institutional Ethics Committees https://www.clinicalstudies.in/how-to-develop-sops-for-institutional-ethics-committees/ Sat, 23 Aug 2025 08:01:33 +0000 https://www.clinicalstudies.in/?p=6524 Read More “How to Develop SOPs for Institutional Ethics Committees” »

]]>
How to Develop SOPs for Institutional Ethics Committees

Step-by-Step Guide to Creating SOPs for Institutional Ethics Committees

Introduction: Why SOPs Are Crucial for Ethics Committees

Standard Operating Procedures (SOPs) are foundational documents that govern the operations of Institutional Ethics Committees (IECs) or Institutional Review Boards (IRBs). SOPs not only ensure consistency, regulatory compliance, and quality assurance but also establish transparency in decision-making processes. Without clear SOPs, ECs are vulnerable to deviations, regulatory findings, and ethical lapses—especially in multicenter, multinational trials.

International agencies like ANZCTR, WHO, ICMR, and AAHRPP emphasize documented procedures as a precondition for EC credibility and accreditation. This article outlines how to draft, review, and implement SOPs aligned with ICH-GCP, local regulations, and accreditation guidelines.

Core Components of an EC SOP Framework

A comprehensive set of SOPs for an ethics committee must cover all key functions and operational domains. These include but are not limited to:

  • Constitution and Composition of the EC
  • Initial and Continuing Review Processes
  • Review of Protocol Amendments and Serious Adverse Events (SAEs)
  • Expedited and Emergency Reviews
  • Conflict of Interest Management
  • Quorum Requirements and Meeting Protocols
  • Record Keeping and Archival
  • Member Training and Evaluation

Each SOP should begin with a clear title, purpose, scope, responsibilities, procedure steps, and associated templates/forms.

Step 1: SOP on EC Constitution and Roles

This SOP outlines the eligibility, selection process, and roles of members. It defines the ideal mix of scientific and non-scientific members, laypersons, legal experts, and gender representation.

Role Minimum Number Qualification
Clinician (Chairperson) 1 MBBS/MD, external to institution
Legal Expert 1 LLB/LLM or experience in medico-legal matters
Layperson 1 Non-scientific, independent member

The SOP should also define tenure, renewal of membership, and frequency of reconstitution.

Step 2: SOP for Protocol Review Process

This SOP must describe how study protocols are received, allocated, and reviewed. Key elements include:

  • Checklist for submission completeness
  • Distribution of protocol to primary and secondary reviewers
  • Review timelines (usually 21–30 days)
  • Decision-making criteria (approval, conditional approval, rejection)

The SOP should reference ICH-GCP E6(R2) standards and define documentation procedures for minutes, vote counts, and dissent opinions.

Step 3: SOP for Expedited and Emergency Review

This SOP applies to minimal risk studies, SAE follow-ups, and protocol deviations. It must define:

  • What qualifies for expedited review (e.g., observational studies, minor amendments)
  • Timelines for review (usually 5–10 days)
  • Reviewer responsibility and documentation

A sample clause could be: “Expedited review decisions must be ratified at the next full board meeting.”

Step 4: SOP for Handling Serious Adverse Events (SAEs)

The EC must receive and review SAE reports promptly. This SOP should define:

  • Timelines: initial report within 24 hours; full report within 14 days
  • SAE review committee constitution
  • Reporting to DCGI (India) or relevant authority

It should also explain how to assess causality, severity, and protocol violation linkage.

Step 5: SOP on Conflict of Interest and Quorum

Each EC SOP manual must contain a standalone section on identifying and managing conflicts of interest (COI). This should include:

  • Declaration forms for members
  • Recusal procedures during protocol discussion
  • Documentation of COI in meeting minutes

Quorum SOP should specify minimum members and mandatory presence of at least one layperson and one member from a non-affiliated institution.

Step 6: SOP on Record Retention and Documentation

This SOP defines how EC records are stored, accessed, and archived. Key points include:

  • Retention period: minimum of 3–5 years post-study closure
  • Access controls and audit trails
  • Backup procedures and disaster recovery plans

Digital recordkeeping systems should be compliant with 21 CFR Part 11 (if used).

Step 7: SOP on Member Training and Capacity Building

Ongoing competency of EC members is vital. This SOP should include:

  • Initial orientation covering ICH-GCP, Schedule Y, and local laws
  • Annual training and documentation
  • Assessment through quizzes or audit feedback

Sample training log fields: Date, Topic, Trainer, Signature, Evaluation Result.

Best Practices for SOP Development and Review

Follow these best practices to ensure quality and regulatory compliance:

  • Involve multidisciplinary EC members in SOP drafting
  • Use version control with effective and superseded dates
  • Include flowcharts and decision trees for complex procedures
  • Establish annual SOP review and revision cycle

Challenges in SOP Implementation and How to Overcome Them

Common hurdles include lack of buy-in, resistance to documentation, and SOP overload. Address these through:

  • Training sessions emphasizing the role of SOPs in protecting trial subjects
  • Templates and SOP writing workshops
  • Creating a SOP compliance dashboard for audit readiness

Conclusion: SOPs as the Backbone of EC Accountability

Developing and implementing SOPs for Institutional Ethics Committees is not just a regulatory checkbox—it’s a commitment to ethical rigor and procedural fairness. SOPs empower ECs to operate transparently, review protocols consistently, and safeguard participant rights effectively. With proper structure, periodic review, and institutional support, SOPs become living documents that elevate the credibility of the ethics review process in every clinical trial setting.

]]>
SOP for EC/IRB Continuing Review and Renewals https://www.clinicalstudies.in/sop-for-ec-irb-continuing-review-and-renewals/ Thu, 07 Aug 2025 15:52:32 +0000 ]]> https://www.clinicalstudies.in/sop-for-ec-irb-continuing-review-and-renewals/ Read More “SOP for EC/IRB Continuing Review and Renewals” »

]]>
SOP for EC/IRB Continuing Review and Renewals

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-EC-IRB-Continuing-Review-and-Renewals”
},
“headline”: “SOP for Ethics Committee and IRB Continuing Review and Renewals”,
“description”: “This SOP outlines the regulatory-compliant process for EC/IRB continuing review and renewals to maintain ethical oversight of clinical trials, aligned with ICH GCP, FDA, EMA, CDSCO, and WHO guidelines.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for EC/IRB Continuing Review and Renewals

Department Clinical Research
SOP No. CR/ETH/007/2025
Supersedes NA
Page No. 1 of 21
Issue Date 26/08/2025
Effective Date 01/09/2025
Review Date 01/09/2026

Purpose

The purpose of this SOP is to describe the process for conducting Ethics Committee (EC) and Institutional Review Board (IRB) continuing reviews and renewals of clinical trials. This ensures ongoing ethical oversight, participant protection, and compliance with ICH-GCP, WHO, FDA, EMA, and CDSCO regulatory requirements.

Scope

This SOP applies to all clinical research staff, investigators, regulatory affairs personnel, and quality assurance officers involved in the preparation, submission, and follow-up of EC/IRB continuing review and renewal applications for clinical trials.

Responsibilities

  • Principal Investigator (PI): Prepares progress reports and renewal documents for submission to EC/IRB.
  • Regulatory Affairs Manager: Coordinates submissions and ensures compliance with regional requirements.
  • Clinical Research Associate (CRA): Collects site-level data and ensures accuracy of reports.
  • Quality Assurance Officer: Reviews documents for completeness and compliance with applicable guidelines.
  • Head of Clinical Research: Approves submissions before dispatch to EC/IRB.

Accountability

The Regulatory Affairs Head is accountable for ensuring that continuing review and renewal applications are submitted on time, complete, and compliant. Failure to maintain approvals may result in trial suspension or regulatory non-compliance.

Procedure

1. Identification of Renewal Requirement
Determine the renewal due date based on EC/IRB initial approval letter.
Notify PI and study team at least 60 days before renewal deadline.

2. Preparation of Renewal Package
Include protocol progress report, enrollment status, safety summary (AE/SAE reports), deviations, amendments since last approval, and updated Investigator’s Brochure if applicable.
Ensure all documents are updated and signed by responsible personnel.

3. Internal Review
QA reviews renewal package for completeness.
Head of Clinical Research reviews and approves the package.

4. Submission to EC/IRB
Submit renewal package in electronic or paper form as per EC/IRB requirements.
File proof of submission in Regulatory Communication Log.

5. Approval Tracking
Maintain EC/IRB Renewal Tracker with submission and approval dates.
Follow up until approval is received.

6. Post-Approval Implementation
Communicate approval to trial sites and sponsor.
Implement EC/IRB conditions, if any, prior to continuing the trial.

Abbreviations

  • SOP: Standard Operating Procedure
  • EC: Ethics Committee
  • IRB: Institutional Review Board
  • PI: Principal Investigator
  • CRA: Clinical Research Associate
  • QA: Quality Assurance
  • AE: Adverse Event
  • SAE: Serious Adverse Event
  • TMF: Trial Master File

Documents

  1. EC/IRB Renewal Checklist (Annexure-1)
  2. EC/IRB Renewal Tracker (Annexure-2)
  3. Regulatory Communication Log (Annexure-3)

References

  • ICH E6(R2) – Good Clinical Practice
  • US FDA 21 CFR Part 56 – IRB Requirements
  • EMA Clinical Trial Regulation (EU No. 536/2014)
  • WHO Guidelines for Ethics Committees
  • CDSCO Clinical Trial Rules, India (2019)

Version: 1.0

Approval Section

Prepared By Rajesh Kumar, Regulatory Affairs Specialist
Checked By Sunita Reddy, QA Officer
Approved By Dr. Anil Sharma, Head of Clinical Research

Annexures

Annexure-1: EC/IRB Renewal Checklist

Document Included (Yes/No) Remarks
Protocol Progress Report Yes Covering Jan–Jun 2025
Safety Summary Yes All SAEs included
Updated Investigator’s Brochure Yes Version 5.0 submitted

Annexure-2: EC/IRB Renewal Tracker

Submission Date EC/IRB Name Approval Date Status Remarks
05/09/2025 Metro Ethics Committee 25/09/2025 Approved Annual renewal granted

Annexure-3: Regulatory Communication Log

Date Authority Query Response Responsible Person
15/09/2025 Metro EC Provide SAE follow-up details Submitted updated safety table Rajesh Kumar

Revision History

Revision Date Revision No. Revision Details Reason for Revision Approved By
26/08/2025 00 Initial version New SOP creation Head, Clinical Research

For more SOPs visit: Pharma SOP

]]>